Raymond James Financial
RCKT icon

Raymond James Financial’s Rocket Pharmaceuticals RCKT Stock Holding History

Raymond James Financial’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$542K Buy
158,502
+9,295
+6% +$30.9K ﹤0.01% 4448
2026
Q1 		$534K Buy
149,207
+30,461
+26% +$121K ﹤0.01% 4300
2025
Q4 		$417K Sell
118,746
-11,112
-9% -$38K ﹤0.01% 4385
2025
Q3 		$423K Buy
129,858
+7,188
+6% +$22.6K ﹤0.01% 4222
2025
Q2 		$301K Buy
122,670
+91,093
+288% +$461K ﹤0.01% 4293
2025
Q1 		$211K Buy
31,577
+8,932
+39% +$88.2K ﹤0.01% 4394
2024
Q4 		$285K Buy
+22,645
New +$341K ﹤0.01% 4205

Other funds holding RCKT

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Raymond James Financial's RCKT Position: Q2 2026 in Review

Raymond James Financial increased its Rocket Pharmaceuticals (RCKT) stake by 6.2% in Q2 2026, buying an estimated $30.9K and bringing the position to 158,502 shares worth $542K. The position accounts for ﹤0.01% of the portfolio, ranked #4448.

Raymond James Financial first reported a position in RCKT in Q4 2024 and has held it in 7 quarters since. 180 funds tracked by Wall St. Rank hold RCKT as of Q2 2026.

  • Raymond James Financial held 158,502 shares of Rocket Pharmaceuticals worth $542K as of Q2 2026.
  • Raymond James Financial bought 9,295 Rocket Pharmaceuticals shares in Q2 2026, an estimated $30.9K.
  • Rocket Pharmaceuticals made up ﹤0.01% of Raymond James Financial's portfolio in Q2 2026, its #4448 holding.
  • Raymond James Financial first reported a position in Rocket Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
  • 180 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q2 2026.

Based on Raymond James Financial's 13F filing for Q2 2026, filed 14 Aug 2026.